This thesis on the pharmacological management of osteoporosis provides a comprehensive analysis of current treatment strategies, highlighting their mechanisms, efficacy, and limitations. It effectively discusses the pathophysiology of bone loss, emphasizing key molecular pathways like RANKL-OPG and Wnt signaling. The evaluation of anti-resorptive and anabolic therapies, including bisphosphonates, Denosumab, and newer agents like Romosozumab, is well-structured and supported by relevant clinical data. The discussion on treatment challenges, such as adherence issues and long-term safety concerns, adds depth to the analysis. Additionally, the thesis presents future directions, advocating for personalized medicine and optimized treatment sequencing. Overall, it is a well-researched and insightful contribution to understanding osteoporosis management